natgillin/translations-raw huggingface dataset:
Patients taking these medicinal products with levodopa/carbidopa should be carefully monitored for loss of therapeutic response.
Pri bolnikih, ki jemljejo ta zdravila skupaj z levodopo/karbidopo, je treba skrbno spremljati morebitno zmanjšanje terapevtskega odziva.
Patients taking Volibris should have their haemoglobin and/or haematocrit levels measured regularly.
Bolnikom, ki jemljejo zdravilo Volibris, je treba redno kontrolirati hemoglobin in/ali hematokrit.
Patients taking warfarin should undergo regular monitoring of the INR, especially after any changes in Lojuxta dosage.
Pri bolnikih, ki jemljejo varfarin, je treba redno spremljati INR, predvsem po spremembah odmerka zdravila Lojuxta.
Patients taking Xyrem should avoid alcohol, as it can increase Xyrem’s effects.
Bolniki, ki jemljejo zdravilo Xyrem, se morajo izogibati alkoholu, saj lahko ta poveča učinke zdravila Xyrem.
Patients taking Xyrem should stop breast feeding.
Bolnice, ki jemljejo zdravilo Xyrem, morajo prenehati dojiti.
Patients that have previously been treated with other bile acids or other cholic acid preparations should be closely monitored in the same manner during the initiation of treatment with Kolbam.
Bolnike, ki so se predhodno zdravili z drugimi žolčnimi kislinami ali drugimi pripravki holne kisline, je treba med uvajanjem zdravljenja z zdravilom Kolbam skrbno spremljati na enak način.
Patients titrating selexipag to an individually tolerated dose (200 micrograms twice daily increments up to 800 micrograms twice daily; N = 33) achieved a statistically significant mean reduction in pulmonary vascular resistance of 30.3% (95% confidence interval [CI]: 44.7%, 12.2%; p = 0.0045) and an increase in cardiac index (median treatment effect) of 0.41 L/min/m2 (95% CI: 0.10, 0.71) compared to placebo (N = 10).
Bolniki, ki so seleksipag titrirali do odmerka, ki so ga individualno še prenašali (postopno povečevanje 200 mikrogramov dvakrat na dan do 800 mikrogramov dvakrat na dan; N = 33), so dosegli statistično značilno povprečno zmanjšanje pljučnega žilnega upora 30,3 % (95-% interval zaupanja [IZ]: 44,7 %, 12,2 %; p = 0,0045) in povečanje srčnega indeksa (mediani učinek zdravljenja) za 0,41 l/min/m2 (95-% IZ: 0,10; 0,71) v primerjavi s placebom (N = 10).
Patients transferred to NovoMix 30 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products.
Bolniki, ki preidejo na zdravilo NovoMix 30 z druge vrste insulina, utegnejo potrebovati večje število dnevnih injekcij ali drugačen odmerek kot med uporabo svojih običajnih insulinskih zdravil.
Patients transferred to NovoMix 50 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products.
Bolniki, ki preidejo na zdravilo NovoMix 50 z druge vrste insulina, utegnejo potrebovati večje število dnevnih injekcij ali drugačen odmerek kot med uporabo svojih običajnih insulinskih zdravil.
Patients transferred to NovoMix 70 from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products.
Bolniki, ki preidejo na zdravilo NovoMix 70 z druge vrste insulina, utegnejo potrebovati večje število dnevnih injekcij ali drugačen odmerek kot med uporabo svojih običajnih insulinskih zdravil.
Patients treated
Bolniki,
Patients treated for prevention of VTEs after hip or knee replacement surgery, dosing should be reduced to 150 mg taken once daily as 2 capsules of 75 mg Pradaxa if they receive concomitantly dabigatran etexilate and amiodarone (see section 4.2).
Bolnikom, ki prejemajo zdravljenje za preprečitev VTE po operativni vstavitvi umetnega kolka ali kolena, odmerjanje Pradaxe zmanjšamo na 150 mg, to je 2 kapsuli po 75 mg enkrat na dan, če prejemajo dabigatran eteksilat sočasno z amiodaronom (glejte poglavje 4.2).
Patients treated for prevention of VTEs after hip or knee replacement surgery, dosing should be reduced to 150 mg taken once daily as 2 capsules of 75 mg Pradaxa if they receive concomitantly dabigatran etexilate and amiodarone (see section 4.2).
Bolnikom, ki prejemajo zdravljenje za preprečitev VTE po operativni vstavitvi umetnega kolka ali kolena, odmerjanje zdravila Pradaxa zmanjšamo na 150 mg, to je 2 kapsuli po 75 mg enkrat na dan, če prejemajo dabigatran eteksilat sočasno z amiodaronom (glejte poglavje 4.2).
Patients treated for prevention of VTEs after hip or knee replacement surgery, dosing should be reduced to 150 mg taken once daily as 2 capsules of 75 mg Pradaxa if they receive concomitantly dabigatran etexilate and quinidine (see section 4.2).
Bolnikom, ki prejemajo zdravljenje za preprečitev VTE po operativni vstavitvi umetnega kolka ali kolena, odmerjanje zdravila Pradaxa zmanjšamo na 150 mg, to je 2 kapsuli po 75 mg enkrat na dan, če prejemajo dabigatran eteksilat sočasno s kinidinom (glejte poglavje 4.2).
Patients treated prophylactically with micafungin were those undergoing haematopoetic stem cell transplantation (HSCT) who were at high risk for fungal infections.
Bolniki, ki so prejemali mikafungin za preprečevanje glivičnih okužb, so bili bolniki po presaditvi hematopoetskih matičnih celic pri katerih je bilo tveganje za glivične okužbe veliko.
Patients treated with any antipsychotic medicinal products, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).
Bolnike, ki dobivajo kateri koli antipsihotik, vključno z aripiprazolom, je treba opazovati glede znakov in simptomov hiperglikemije (npr. polidipsije, poliurije, polifagije in šibkosti); bolnike s sladkorno boleznijoali dejavniki tveganja zanjo pa je treba redno nadzirati, da bi odkrili poslabšanje urejenosti glukoze (glejte poglavje 4.8).
Patients treated with any antipsychotic medicinal products, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).
Bolnike, ki dobivajo kateri koli antipsihotik, vključno z aripiprazolom, je treba opazovati glede znakov in simptomov hiperglikemije (npr. polidipsije, poliurije, polifagije in šibkosti); bolnike z diabetesom m(glejte poglavje 4.8)ellitusom ali dejavniki tveganja zanj pa je treba redno nadzirati, da bi odkrili poslabšanje urejenosti glukoze .
Patients treated with any antipsychotic medicinal products, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).
Bolnike, ki dobivajo kateri koli antipsihotik, vključno z aripiprazolom, je treba opazovati glede znakov in simptomov hiperglikemije (npr. polidipsije, poliurije, polifagije in šibkosti); bolnike z diabetesom mellitusom ali dejavniki tveganja zanj pa je treba redno nadzirati, da bi odkrili poslabšanje urejenosti glukoze (glejte poglavje 4.8) .
Patients treated with any antipsychotic medicinal products, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).
Bolnike, ki dobivajo kateri koli antipsihotik, vključno z aripiprazolom, je treba opazovati glede znakov in simptomov hiperglikemije (npr. polidipsije, poliurije, polifagije in šibkosti); bolnike z diabetesom mellitusom ali dejavniki tveganja zanj pa je treba redno nadzirati, da bi odkrili poslabšanje urejenosti glukoze (glejte poglavje 4.8).
Patients treated with any antipsychotic medicinal products, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).
Bolnike, ki prejemajo kateri koli antipsihotik, vključno s aripiprazolom, je treba opazovati za znaki in simptomi hiperglikemije (npr. polidipsije, poliurije, polifagije in šibkosti), bolnike, ki imajo sladkorno bolezen ali dejavnike tveganja zanjo, pa redno spremljati, da bi odkrili poslabšanje uravnavanja glukoze (glejte poglavje 4.8).
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter .
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z olanzapinom, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z olanzapinom, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike , npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z olanzapinom, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z olanzapinom, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z olanzapinom, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let..
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z olanzapinom, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let..
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom olanzapinom, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku zdravljenja, po 12 tednih zdravljenja z olanzapinom, nato pa na vsakih 5 let.
Patients treated with any antipsychotic medicines, including olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom olanzapinom, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku zdravljenja, po 12 tednih zdravljenja z olanzapinom, nato pa na vsakih pet let.
Patients treated with any antipsychotic medicines, including olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z olanzapinom moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
Patients treated with any antipsychotic medicines, including olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom olanzapina, moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
Patients treated with any antipsychotic medicines, including olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom ZYPREXA, moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
Patients treated with any antipsychotic medicines, including ZYPREXA VELOTAB, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom ZYPREXA VELOTAB, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
Patients treated with any antipsychotic medicines, including ZYPREXA VELOTAB, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom ZYPREXA VELOTAB, moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
Patients treated with any antipsychotic medicines, including ZYPREXA, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom ZYPREXA, moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
Patients treated with any antipsychoticmedicines, including ZYPADHERA, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom ZYPADHERA, moramo redno spremljati glede lipidov, v skladu z znanimi priporočili za antipsihotike, npr. na začetku, 12 tednov po začetku jemanja olanzapina in nato vsakih 5 let.
Patients treated with any atypical antipsychotic, including Xeplion, should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom Xeplion, moramo opazovati za simptome hiperglikemije (kot so polidipsija, poliurija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo glede poslabšanja nadzora koncentracije glukoze v krvi.
Patients treated with Benepali should be given the Patient Alert Card.
Bolniki, ki se zdravijo z zdravilom Benepali, naj prejmejo opozorilno kartico za bolnika.
Patients treated with Brintellix can abruptly stop taking the medicinal product without the need for a gradual reduction in dose (see section 5.1).
Bolniki, ki se zdravijo z zdravilom Brintellix, lahko brez potrebe po postopnem zmanjševanju odmerka nenadno prenehajo z jemanjem zdravila (glejte poglavje 5.1).
Patients treated with Caprelsa must be given the patient alert card and be informed about the risks of Caprelsa (see also package leaflet).
Bolniki, zdravljeni z zdravilom Caprelsa, morajo dobiti Opozorilno kartico za bolnika in jih je treba seznaniti s tveganji zdravila Caprelsa (glejte tudi navodilo za uporabo).
Patients treated with CHAMPIX had a superior rate of CO-confirmed abstinence during weeks
Bolniki, zdravljeni z zdravilom CHAMPIX, so imeli boljšo s CO preverjeno abstinenco od
Patients treated with ciclosporin and Rapamune beyond 3 months had higher serum creatinine levels and lower calculated glomerular filtration rates compared to patients treated with ciclosporin and placebo or azathioprine controls.
Bolniki, ki so se zdravili s ciklosporinom in zdravilom Rapamune več kot 3 mesece, so imeli višje koncentracije serumskega kreatinina in manjšo izračunano hitrost glomerulne filtracije kot bolniki, zdravljeni s ciklosporinom in placebom, ali azatioprinska kontrolna skupina.
Patients treated with Cosentyx 150 mg showed improvements in spinal mobility as measured by change from baseline in BASMI at Week 16 for both AS Study 1 (-0.40 versus -0.12 for placebo; p=0.0114) and AS Study 2 (-0.51 versus -0.22 for placebo; p=0.0533).
Pri bolnikih, ki so prejemali zdravilo Cosentyx v odmerku 150 mg, je prišlo do izboljšanja gibljivosti hrbtenice, kar so ocenjevali s spremembo vrednosti Bachovega indeksa gibljivosti hrbtenice BASMI od izhodišča po 16 tednih, in sicer tako v 1. študiji ankilozirajočega spondilitisa (-0,40 v primerjavi z -0,12 pri uporabi placeba; p=0,0114) kot v 2. študiji ankilozirajočega spondilitisa (-0,51 v primerjavi z -0,22 pri uporabi placeba; p=0,0533).
Patients treated with Entyvio should be monitored for any new onset or worsening of neurological signs and symptoms such as those listed below:
Bolnike, ki se zdravijo z zdravilom Entyvio, je treba nadzirati glede pojava kakršnih koli novih ali poslabšanja že prisotnih nevroloških znakov in simptomov, kot so:
Patients treated with Fexeric should not receive concomitant treatment with other oral iron preparations.
Bolniki, zdravljeni z zdravilom Fexeric, se ne smejo sočasno zdraviti z drugimi peroralnimi pripravki železa.
Patients treated with Flixabi should be given the package leaflet and the special Alert card.
Bolniki, zdravljeni z zdravilom Flixabi, pa morajo dobiti navodilo za uporabo in posebno opozorilno kartico.
Patients treated with Herceptin are at increased risk for developing CHF (New York Heart Association [NYHA] Class II-IV) or asymptomatic cardiac dysfunction.
Pri bolnikih, ki so se zdravili z zdravilom Herceptin, obstaja večje tveganje za pojav kongestivnega srčnega popuščanja (New York Heart Association – NYHA, razred IIIV) ali asimptomatične motnje v delovanju srca.
Patients treated with Humira had significantly reduced risk of disease flare during the initial 12 weeks of treatment.
Bolniki, zdravljeni z zdravilom Humira, so imeli statistično pomembno zmanjšanje tveganja novega izbruha bolezni v začetnih 12. tednih zdravljenja.
Patients treated with Humira should be given the special alert card.
Bolniki, ki se zdravijo z zdravilom Humira, morajo dobiti posebno opozorilno kartico za bolnike.
Patients treated with ibandronic acid should be given the package leaflet and the patient reminder card.
Bolniki, ki se zdravijo z ibandronsko kislino, morajo dobiti navodilo za uporabo in opozorilno kartico za bolnika.
Patients treated with immunosuppressants, including Advagraf are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal).
Pri bolnikih, ki se zdravijo z zdravili za zaviranje imunske odzivnosti, vključno z zdravilom Advagraf, obstaja večje tveganje za pojav oportunističnih okužb (bakterijskih, glivičnih, virusnih in protozojskih).
Patients treated with immunosuppressants, including Envarsus are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal).
Pri bolnikih, zdravljenih z imunosupresivi, vključno z zdravilom Envarsus, je večje tveganje za oportunistične okužbe (bakterijske, glivične, virusne in protozojske).
Patients treated with immunosuppressants, including Modigraf, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal).
Pri bolnikih, ki se zdravijo z zdravili za zaviranje imunske odzivnosti, vključno z zdravilom Modigraf, obstaja večje tveganje za pojav oportunističnih okužb (bakterijskih, glivičnih, virusnih in protozojskih).
Patients treated with Inflectra should be given the package leaflet and the special Alert card.
Bolniki, zdravljeni z zdravilom Inflectra, pa morajo dobiti Navodilo za uporabo in posebno opozorilno kartico.
Patients treated with Kentera experienced a highly statistically significant decrease in the number of urinary incontinence episodes per day from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p<0.0001), as well as for the secondary endpoints: a decrease in the average daily urinary frequency (p=0.0017), and an increase in the average urine volume per void (p=0.0018).
Pri bolnikih, ki so prejemali zdravilo Kentera, se je število epizod urinarne inkontinence na dan statistično zelo pomembno zmanjšalo od izhodiščne točke do cilja študije (primarni cilj študije) v primerjavi s placebom (p < 0,0001), enako pa velja tudi za sekundarna cilja študije: zmanjšanje povprečne dnevne urinarne frekvence (p = 0,0017) in povečanje povprečne prostornine urina na uriniranje (p = 0,0018).
Patients treated with Kuvan must continue a restricted phenylalanine diet and undergo regular clinical assessment (such as monitoring of blood phenylalanine and tyrosine levels, nutrient intake, and psycho- motor development).
Bolniki, ki se zdravijo z zdravilom Kuvan, morajo nadaljevati s prehrano z omejenim vnosom fenilalanina ter potrebujejo redno klinično oceno (kot je spremljanje ravni fenilalanina in tirozina v krvi, vnos hranil in psihomotorični razvoj).